



Interview with:
Manel Chikh, CEO, Zaphyr Pharma

Dr. Manel Chikh is the founder and CEO of Zaphyr Pharmaceuticals, a pharma company that commercialize specialty products in the MEA region. Founded in 2012, Zaphyr focuses on oncology and rare diseases and operates between Switzerland, Ireland and Dubai.



Given your expertise in the MEA region, how would you assess the present state of the GCC market and across the wider region?

The MEA market faced a slowdown last year, primarily driven by the oil crisis in key countries such as Saudi Arabia and Algeria, and currency devaluation and economic crises in other countries, Egypt for example.

Governments across the region reacted by increasing their focus on cost containments impacting the healthcare budget, for example Saudi Arabia reduced the annual tender opportunity for selected products leading to a significant decline in revenues for many international companies operating in the region.

However, recent performance indicators show that many countries are recovering slowly, and we can still anticipate the MEA region to be among the fastest growing pharma market regions globally in the near future. The main revenue driver for the majority of multinational companies will remain the innovative medicines portfolio. However, the companies who will diversify into generics, consumer medicines, diagnostics and other related healthcare markets will find interesting growth opportunities. Generics are expected to represent half of all sales in 2017 and will continue to grow.

What opportunities does the market present in your region?

Government policies and efforts across the MEA region to reduce drug spending whilst simultaneously improving access to quality and cost effective medicines for patients has resulted in the strong performance of generics. Affordability will be the key consideration for both payers and patients, and the most cost-effective options will typically be generics.

Local and regional players and manufacturers are encouraged to develop a larger product portfolio to fulfil national needs. For example, it was announced in January 2017 that as part of the UAE's strategy to decrease the cost of medicines and limit the country's escalating healthcare bill, the Emirates' Ministry of Health plans to increase the number of generic drug manufacturing facilities in the UAE to 30 by 2020.

Innovative drugs will continue to be welcomed in the region. In the GCC for example, the Ministries of Health encourage faster market access to highly innovative diagnostics and medicines, making it a priority to provide patients with the best available treatments. As a consequence, many FDA/EU approved innovative products can be commercialized in just few months in some countries, through specific early access programs before registration.

What are the obstacles in the MEA region that market entrants should be aware of?

The MEA region is one of the most complex markets to penetrate and operate in due to the fact that each country has its own rules, standards and systems across regulatory, market access and pricing.

The GCC countries have already started a harmonization process to improve this, so for example when a product is approved in one of the GCC countries it can then be marketed in the others. However this is still a work in progress and will take some time to be fully adopted.

Local business practices can also act as a barrier for foreign companies. Several countries, such as Algeria, have policies that provide price or access advantages to local manufacturers, making it very difficult for foreign companies to import products, which have been manufactured abroad.

How do you see the region developing in the coming years?

The MEA region is expected to be among the fastest growing pharma markets globally. Market data shows that the region is expected to reach \$50 billion in the next 5 years. The drivers are the increase of the number of patients suffering from chronic diseases and the requirement of better access to a more sophisticated healthcare system.

By representing approximately 3% of global pharmaceutical sales, the MEA region will continue to attract new players. To be successful in the region, companies will have to be committed and engaged with key stakeholders from each market - health authorities, physicians, payers and patients. This will require flexibility to navigate the complexities of each market, manage fluctuating prices and make difficult decisions to optimize margins, volumes and the investment required to build the path to market and patient.

How do you think the launch of the CPH MEA event will impact business in your own country and the wider region?

Each CPH event is an opportunity to meet new key players, to develop your API or finished dose portfolio, to develop and expand manufacturing and/or commercialization capabilities in new territories and to receive updates on all the new trends. Thanks to CPH, I met many outstanding partners with whom I built a strong and successful long-term presence in the MEA region.

I fully support and recommend the launch of CPH MEA. This event will be a fantastic opportunity to highlight the region to the wider pharma market and to give foreign companies real exposure to the potential opportunities it offers.

To learn more about CPH Middle East & Africa and to register your interest to exhibit at the event, visit: gotocphi.com/mea today!

